FBR & Co. disclosed Alexion Pharma (NASDAQ:ALXN), hiking its stock price target to $92.00 earlier today
- Updated: September 15, 2016
In a statement issued on 9/16/2016 FBR & Co. increased the target price of Alexion Pharma (NASDAQ:ALXN) from $82 to $92 indicating a possible downside of -0.29%.
Having a price of $129.70, Alexion Pharma (NASDAQ:ALXN) traded 2.07% higher on the day. With the last close down 5.11% from the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same time. ALXN has registered a 50-day moving average of $131.08 and 200-day moving average of $136.39. Trading volume was was down over the average, with 972,609 shares of ALXN changing hands under the typical 1,844,360 shares.
See Graphic Below:
Alexion Pharma has a 52 week low of $110.56 and a one-year high of $193.45 with a price-earnings ratio of 325 and has a market capitalization of $0.0.
Also covering Alexion Pharma’s target price, a total of 18 firms have released a report on ALXN. The one year target is $187.61 with seven firms rating the company a strong buy, six firms rating the stock a buy, seven analyts rating the stock a hold, 0 rating the company to underperform, and lastly 0 brokeragesrating the stock as sell.
About Alexion Pharma (NASDAQ:ALXN)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical programs include Soliris (eculizumab), ALXN 1101, ALXN 1007, SBC-103, ALXN 1210 and ALXN 5500. It offers Soliris for patients with either paroxysmal nocturnal hemoglobinuria (PNH), a life-threatening and ultra-rare genetic blood disorder, or atypical hemolytic uremic syndrome (aHUS), and a life-threatening and ultra-rare genetic disease. Strensiq is a targeted enzyme replacement therapy. It offers Kanuma for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). ALXN 1007 is a humanized antibody designed to target inflammatory disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.